Exceptional Response to Cabozantinib of Rapidly Evolving Brain Metastases of Renal Cell Carcinoma: A Case Report and Review of the Literature
- PMID: 30005936
- DOI: 10.1016/j.clgc.2018.06.005
Exceptional Response to Cabozantinib of Rapidly Evolving Brain Metastases of Renal Cell Carcinoma: A Case Report and Review of the Literature
Keywords: Antiangiogenic targeted agents; Blood–brain barrier penetration; Brain metastases; Complete response; RCC.
Similar articles
-
Activity of cabozantinib in radioresistant brain metastases from renal cell carcinoma: two case reports.J Med Case Rep. 2018 Nov 25;12(1):351. doi: 10.1186/s13256-018-1875-9. J Med Case Rep. 2018. PMID: 30474572 Free PMC article.
-
In brief: Cabozantinib (Cabometyx) for advanced renal cell carcinoma.Med Lett Drugs Ther. 2016 Jul 18;58(1499):e97. Med Lett Drugs Ther. 2016. PMID: 27403787 No abstract available.
-
Cabozantinib improves clinical outcomes in renal cancer.Lancet Oncol. 2017 Jan;18(1):e2. doi: 10.1016/S1470-2045(16)30620-9. Epub 2016 Nov 25. Lancet Oncol. 2017. PMID: 27890466 No abstract available.
-
Cabozantinib use in renal cell carcinoma.Drugs Today (Barc). 2017 May;53(5):299-307. doi: 10.1358/dot.2017.53.5.2623107. Drugs Today (Barc). 2017. PMID: 28650002 Review.
-
Cabozantinib: A Review in Advanced Renal Cell Carcinoma.Drugs. 2016 Dec;76(18):1771-1778. doi: 10.1007/s40265-016-0661-5. Drugs. 2016. PMID: 27909994 Review.
Cited by
-
An Overview of Systemic Targeted Therapy in Renal Cell Carcinoma, with a Focus on Metastatic Renal Cell Carcinoma and Brain Metastases.Curr Issues Mol Biol. 2023 Sep 21;45(9):7680-7704. doi: 10.3390/cimb45090485. Curr Issues Mol Biol. 2023. PMID: 37754269 Free PMC article. Review.
-
Discovery and Optimization of the First ATP Competitive Type-III c-MET Inhibitor.J Med Chem. 2023 Jul 13;66(13):8782-8807. doi: 10.1021/acs.jmedchem.3c00401. Epub 2023 Jun 21. J Med Chem. 2023. PMID: 37343272 Free PMC article.
-
RET signaling pathway and RET inhibitors in human cancer.Front Oncol. 2022 Jul 25;12:932353. doi: 10.3389/fonc.2022.932353. eCollection 2022. Front Oncol. 2022. PMID: 35957881 Free PMC article. Review.
-
Efficacy of cabozantinib therapy for brain metastases from renal cell carcinoma.IJU Case Rep. 2022 May 3;5(4):293-296. doi: 10.1002/iju5.12459. eCollection 2022 Jul. IJU Case Rep. 2022. PMID: 35795125 Free PMC article.
-
TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase Inhibitors.Cancer Discov. 2021 Jan;11(1):126-141. doi: 10.1158/2159-8290.CD-20-0571. Epub 2020 Oct 1. Cancer Discov. 2021. PMID: 33004339 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
